Calibrs repurposed drug to treat non-viral diarrhea enters into a clinical trial Cryptosporidiosis is one of the leading causes of diarrhea in children under the age of 2 in developing countries, and there is no available treatment approved for use in the pediatric population.1 Childhood diarrheal diseases are not only the second leading cause of death in children under 5, causing 525,000 deaths annually, they are also a leading cause of malnutrition, which is associated with growth stunting and poor cognitive development.2 In immunocompromised individuals, cryptosporidiosis can be life-threatening, since there is no fully effective drug treatment. Calibr has now identified and repurposed an FDA-approved drug, clofazimine, used for decades to treat leprosy, as a potential new treatment for cryptosporidiosis.
Clofazimine was identified as part of a concerted effort at Calibr to repurpose known drugs, in the hopes of accelerating the time it takes for innovative research to impact patients. Based on a similar theme, Calibr created a set of chemical compounds called ReFRAME to better mine known drugs. ReFRAME was built with the support of a grant from the Bill & Melinda Gates Foundation. ReFRAME consists of 13,000 high-value compounds and is truly unique among repurposing collections in both scale and comprehensiveness. Because the compounds in this collection are either known drugs or molecules that are advanced in the drug discovery process, a clinical drug candidate can be rapidly generated and accelerated through the development process.
Identification of clofazimine as a potential novel treatment for cryptosporidiosis is the first example of how ReFRAME can help accelerate the development of drugs for new medical needs. In a study published in PLOS on February 3, 2017, a Calibr team led by Principal Investigator Case McNamara showed that clofazimine inhibited proliferation of the Cryptosporidium parasite in a mouse model, resulting in significantly reduced fecal shedding of Cryptosporidium oocysts. Their findings suggest that clofazimine could prove to be an effective treatment for cryptosporidiosis relative to the approved drug, Nitazoxanide, which has little to no efficacy in HIV positive patients and low efficacy in malnourished children. Calibr is collaborating with the University of Washington, who is sponsoring the Phase 2A clinical trial in Malawi, and the Bill and Melinda Gates Foundation to study the safety, tolerability, pharmacokinetics and efficacy of clofazimine in the treatment of cryptosporidiosis in HIV positive patients (clinical trial no. NCT03341767).
We're excited for the results of this trial and we hope to make an important impact against a neglected infectious disease, says Case McNamara. With support from the Bill and Melinda Gates Foundation, work is ongoing at Calibr to develop a special formulation of clofazimine ideally suited to treat children.
Cryptosporidiosis is caused by a parasite, Cryptosporidium, that lives in the intestine of infected humans and animals. It is difficult to eradicate, since the oocysts excreted in feces can remain infectious in certain environments for up to six months, resisting disinfection attempts that include chlorination. Prevalent around the world, the parasite has been implicated in a number of outbreaks across the United States, including one statewide outbreak in 2007 that sickened more than 5,500 individuals and contaminated approximately 450 recreational water venues. Because Cryptosporidium spreads so easily in settings without adequate sanitation and hygiene, the parasite is a serious threat in developing countries.
Calibr's research was performed with support of a grant from the Bill & Melinda Gates Foundation.
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369280/
2 http://www.who.int/mediacentre/factsheets/fs330/en/
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine work toward their next discoveries. The institutes graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. In October 2016, TSRI announced a strategic affiliation with the California Institute for Biomedical Research (Calibr), representing a renewed commitment to the discovery and development of new medicines to address unmet medical needs. For more information, see www.scripps.edu.
# # #
For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8118
press@scripps.edu
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
04/08/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
04/07/2026
April 7 2026, 19:00 (PDT) Detective Conan: Fallen Angel of the Highway Opens in...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
06/05/2026
Polands Miecznik-class frigates are part of the largest contract in Polish shipbuilding history. (Image Credit: PGZ Stocznia Wojenna)...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Riedel Communications today announced the expansion of its leadership structure as part of a strategic initiative to strengthen both its operational management ...
06/05/2026
For nearly three decades, Veteran Production Sound Mixer and Five-time Emmy Award Winner Dirk Sciarrotta has helped define the sonic identity of the long-runnin...
06/05/2026
ZEISS CinCraft LensCore: Cinema Lens Looks for Compositing
Brie Clayton May 6, 2026
0 Comments
ZEISS announces the launch of CinCraft LensCore, a nove...
06/05/2026
Wisycom Solves Extreme RF Challenges Across Miles of Live Action for Gravity Med...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Narrative Entertainment has partnered with Encompass to deliver high-quality subtitling of its Great! network content using the Altitude Intelligence AI assiste...
06/05/2026
SipRadius, widely recognized for making content processing and connectivity secure and seamless, is proud to launch a dramatic new approach to AI content creati...
06/05/2026
When the broadband and media industry gathers at ANGA COM in Cologne from May 19 to 21, Big Blue Marble will be at the forefront. The international broadcast an...
06/05/2026
Cinegy GmbH, a leading developer of software-defined television technology, is proud to exhibit at MPTS for the first time. Visitors to the stand will discover ...
06/05/2026
Val Jeanty Receives 2026 Doris Duke Artist Award Jeanty, a composer, percussionist, and turntablist, is the fourth Berklee recipient of the prestigious award ...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
06/05/2026
When live cycling races and international marathons stretch for miles across cities and countryside, there is no margin for RF failure in live broadcast. As Chi...
06/05/2026
Oberkochen/Germany, May 5, 2026
ZEISS announces the launch of CinCraft LensCore, a novel solution for creating physically based cinematic lens looks for visual...
06/05/2026
SAN JOSE, Calif. - May 6, 2026 - Harmonic (NASDAQ: HLIT) today announced its latest broadband innovations for ANGA COM 2026, highlighting its vision for a new e...
06/05/2026
Statement from Rupert Murdoch, Chairman Emeritus, Fox Corporation on Ted Turner&...
06/05/2026
Friday 8 May on RT One and RT Player
Meet the NSPCA team caring for and protecting animals in need in this six-part series
Fly on the wall, six-part series...
06/05/2026
The race to build the world's most powerful AI factories demands networking ...
06/05/2026
How changes to proteins can alter drug interactions for new precision therapies Scripps Research team maps how chemical modifications to proteins affect drug bi...
05/05/2026
Experts from the world of academia, tech, business, politics and media convened for a Thomson Talks at the Cambridge Disinformation Summit in April. It's th...
05/05/2026
Three phones were hardwired for power and transmission to the truck; camera feat...
05/05/2026
The creative studio behind campaigns for the NBA, Fanatics Sportsbook & Casino, ...
05/05/2026
Nielsen has announced results from a co-viewing pilot program covering February&...
05/05/2026
viztrick AiDi, an on-device AI solution developed by Nippon TV, delivered global...
05/05/2026
ARRI has announced Omnibar, a battery-powered, IP65-rated multi-color LED linear...
05/05/2026
Imagine Communications has announced that France T l visions is the first broadc...
05/05/2026
The Women's National Basketball Association (WNBA) and Bell Media today announced a multiyear agreement to broadcast and stream WNBA games in Canada beginni...
05/05/2026
SVG is proud to announce Warner Bros. Discovery's Techwood Studios in Atlant...
05/05/2026
With no operator required, AutoMic workflow automates talent identification on U...
05/05/2026
A crash in 2015 set the industry back, but this winter proved that drones are he...
05/05/2026
Another year, and more proof that Asia continues to shape some of the world's most exciting new sounds. This year's RADAR artists draw from deep local r...
05/05/2026
The Austin City Limits Music Fest 2026 lineup just dropped, and this year, Spoti...
05/05/2026
New drum machine book campaign incoming
Bjooks have announced that during Superbooth 2026, they will be launching a Kickstarter campaign to fund the product...
05/05/2026
Flagship all-in-one production bundle updated
The latest version of Native Instruments' flagship virtual instrument and plug-in bundle has just been ann...
05/05/2026
Rohde & Schwarz to host RF Testing Innovations Forum 2026, helping design engine...
05/05/2026
L3Harris provides communications, electronic warfare, sensors and mission systems that enable Virginia-class submarine crews to operate with confidence in conte...
05/05/2026
The company grew by 7.6% in net revenue and 16.3% in EBITDA, achieving a 33% inc...
05/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
05/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
05/05/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
Calibrs repurposed drug to treat non-viral diarrhea enters into a clinical trial Cryptosporidiosis is one of the leading causes of diarrhea in children under the age of 2 in developing countries, and there is no available treatment approved for use in the pediatric population.1 Childhood diarrheal diseases are not only the second leading cause of death in children under 5, causing 525,000 deaths annually, they are also a leading cause of malnutrition, which is associated with growth stunting and poor cognitive development.2 In immunocompromised individuals, cryptosporidiosis can be life-threatening, since there is no fully effective drug treatment. Calibr has now identified and repurposed an FDA-approved drug, clofazimine, used for decades to treat leprosy, as a potential new treatment for cryptosporidiosis.
